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Strengths and limitations of this study
 ► We used one of the largest databases of electronic 
health records collected by general practitioners, 
which allowed us to examine the association be-
tween chronic kidney disease and dementia diagno-
sis a real- world primary care setting.
 ► Chronic kidney disease status and stage were strict-
ly defined based on serum creatinine information, 
instead of diagnosis codes with limited validity.
 ► We adjusted for a wide range of comorbidities and 
lifestyle- related factors (eg, smoking status and 
body mass index) in the association between chron-
ic kidney disease and dementia.
 ► Although the positive predictive value of dementia 
diagnosis is known to be high in UK primary care, its 
sensitivity may be low, meaning that the crude in-
cidence rate of dementia might be underestimated.
 ► The lack of details to accurately classify dementia 
subtypes (eg, Alzheimer’s disease, vascular demen-
tia and Lewy body dementia) precluded us from 
analysing the relationship between chronic kidney 
disease and dementia subtypes.
AbStrACt
Objectives To investigate the association between 
chronic kidney disease (CKD) and dementia diagnosis in a 
real- world primary care setting in England.
Design Matched cohort study.
Settings English primary care in the Clinical Practice 
Research Datalink.
Participants People aged ≥18 years with predialysis CKD 
(stages 3–5, defined as two measurements of estimated 
glomerular filtration rate <60 mL/min/1.73 m2 for 
3 months) from 2004 to 2014, and people without known 
CKD who were matched on age, sex, general practice and 
calendar time in a 1:1 ratio.
Primary and secondary outcome measures First- ever 
diagnosis of dementia recorded by GPs. We also examined 
all- cause death as a secondary outcome to discuss 
potential competing risk of mortality in the association 
between CKD and dementia diagnosis.
results In a matched cohort of 242 349 pairs with and 
without CKD (mean age 75.4±9.7 years, 39.3% male), 
the crude incidence rate of dementia diagnosis was 
11.4/1000 and 9.4/1000 person- years, respectively. There 
was an association between CKD status and incident 
dementia diagnosis in the first 6 months of the follow- up 
(adjusted rate ratio (aRR) 1.58, 95% CI 1.44 to 1.74), 
which attenuated after 6 months (aRR 1.12, 95% CI 1.08 
to 1.16). Among patients with CKD, there was no evidence 
of association between CKD stage and incident dementia 
diagnosis; compared with stage 3a, aRR (95% CI) was 
1.04 (0.91 to 1.18) for stage 3b and 0.94 (0.74 to 1.20) 
for stages 4 or 5 in the first 6 months, and 0.97 (0.92 to 
1.01) and 0.89 (0.80 to 0.98) thereafter. We found a strong 
association between worsening CKD stage and all- cause 
mortality.
Conclusion We identified a co- occurrence of detection 
of CKD and dementia in real- world clinical practice and 
a strong competing risk of mortality in the association 
between CKD stage and dementia, while a weak 
association between CKD status and dementia was 
suggested in the long term.
IntrODuCtIOn
The prevalence of both chronic kidney 
disease (CKD) and dementia is increasing 
globally, especially in high- income coun-
tries with ageing populations.1–3 It is known 
that CKD and dementia are both associated 
with an increased healthcare burden.4 5 A 
UK study demonstrated that primary and 
secondary care resource utilisation increased 
after a diagnosis of dementia,4 while another 
UK study suggested that inpatient and outpa-
tient healthcare costs increased, as CKD 
stages deteriorated.5
Both the kidneys and the brain are small- 
vessel organs with haemodynamic similar-
ities, and can be damaged simultaneously. 
Much effort has been devoted to exploring 
the biological mechanisms in the associa-
tion between CKD and dementia to date.6–10 
First, CKD and dementia share cardiovas-
cular risk factors including smoking, obesity 
and diabetes mellitus. In addition, evidence 
suggests that CKD- specific factors, such as 
anaemia and electrolyte disorders (eg, hypo-
natraemia), are associated with dementia. 
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Moreover, poor nutrition and chronic inflammation, 
which are often observed in patients with CKD, could 
contribute to the development of dementia.6 7
Previous studies have reported an approximately 
threefold to fivefold increase in the burden of dementia 
in dialysis patients, compared with the general popula-
tion.11 Among the non- dialysis population, CKD has been 
associated with cognitive dysfunction and/or dementia 
in cross- sectional studies.12 13 A recent Japanese longitu-
dinal cohort study showed that CKD was associated with 
dementia independent of measured vascular risk factors 
and cerebral small- vessel disease (identified by MRI) at 
baseline.14 A meta- analysis of five cohort studies found 
a marginally significant association between decreased 
kidney function (estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73 m2) and incidence of cogni-
tive impairment or dementia (relative risk 1.28, 95% CI 
0.99 to 1.65), and a significant association between albu-
minuria and dementia (relative risk 1.35, 95% CI 1.06 to 
1.73).15
Given that both CKD and dementia incur a healthcare 
burden, it is important to understand the association 
between CKD status or stage and diagnosis of dementia 
in real- world clinical practice. However, according to a 
recent review of the literature, the incidence of dementia 
in early CKD in routine clinical care is unknown.8 There-
fore, using a large contemporary dataset from UK primary 
care, the objectives of current study were (i) to investi-
gate the incidence of dementia diagnoses in patients with 
CKD (stages 3–5, defined as two measurements of eGFR 
<60 mL/min/1.73 m2 for 3 months), compared with those 
without known CKD, and (ii) to investigate whether there 
was a graded increase in the incidence of dementia diag-
noses according to CKD stage (CKD stage 3a, 3b and 4 
or 5), with careful approach to deal with bias inherent 
in the real- world data (eg, by quantifying the extent of 
competing risk of mortality which may affect duration of 
follow- up for dementia diagnoses).
MAterIAlS AnD MethODS
Data sources
General practitioners (GPs) in the UK act as gatekeepers 
to the wider healthcare system, and almost all UK citizens 
are registered with GPs from whom they receive routine 
healthcare. GPs have been using computerised health 
records since the late 1980s to record clinically rele-
vant lifestyle information, clinical events or diagnoses, 
prescriptions, specialist referrals, hospital administra-
tion and immunisation for individual patients. The Clin-
ical Practice Research Datalink (CPRD) is a database of 
anonymised electronic health records made available for 
research. At the time of this study, the CPRD contained 
routinely recorded data for about 7% of the UK popula-
tion, and was deemed broadly representative.16 In order 
to gain more comprehensive information on ethnicity, we 
employed around 60% of CPRD data that were linked to 
Hospital Episodes Statistics (HES) in England.17 The data 
were also linked to the Index of Multiple Deprivation, 
which is a validated, small area- level variable capturing 
the socioeconomic status (SES) of study participants.18 
Patients or the public were not involved in the design, 
conduct, reporting or dissemination of our research.
Study population
All individuals aged 18 years or older with data in the 
HES- linked CPRD from 1 April 2004 to 31 March 2014 
were potentially eligible for inclusion, according to the 
following criteria: (i) 1 year after practice registration, 
to ensure that medical information from previous GPs 
had been incorporated in the electronic health records 
of current GPs19; (ii) the date that the practice reached 
CPRD quality control standards, in terms of data quality16 
and (iii) after 1 April 2004, when the Quality and 
Outcomes Framework was introduced, enhancing kidney 
function tests in primary care in the UK.20 We excluded 
patients on renal replacement therapy (haemodialysis, 
peritoneal dialysis or kidney transplantation) because our 
research focus lay on the association between predialysis 
CKD and dementia.
CKD cohort
Patients with CKD at stages 3–5 were identified based 
on two consecutive measurement of eGFR <60 mL/
min/1.73 m2, >3 months apart.21 eGFR was calculated 
from serum creatinine records in CPRD using the Chronic 
Kidney Disease Epidemiology Collaboration equation,22 
after having applied the correction factor of 0.95 to the 
recorded serum creatinine levels to allow for uncalibrated 
creatinine measurements. The patients were included in 
the CKD cohort on the date when their second eGFR was 
<60 mL/min/1.73 m2 (index date).
Matched comparison cohort (no-known CKD cohort)
To establish a comparison group, people without known 
CKD were randomly selected from the rest of the study 
population (ie, people without known CKD in stages 3–5) 
(figure 1). For each patient with CKD (stages 3–5), we 
randomly selected a person without known CKD of the 
same age and sex from the same practice, at the same 
calendar time as the start of the follow- up. Matching 
based on age, sex, general practice and calendar time 
is justified because CKD status largely depends on age 
and sex,23 while the identification and management of 
CKD and dementia can vary across general practice and 
calendar time.
Outcome
The outcome of interest was the incident diagnosis 
of dementia, based on diagnosis codes (Read codes) 
recorded in the CPRD by GPs.24 25 Dementia here includes 
Alzheimer’s disease, vascular dementia and other types 
of dementia such as Lewy body dementia (a code list is 
shown in online supplementary table S1). In this study, we 
did not differentiate between dementia subtypes because 
(i) it is generally difficult to differentiate between them 
in real- world clinical practice and (ii) many patients had 
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Figure 1 Flow chart of the selection of eligible patients with 
and without chronic kidney disease. CKD, chronic kidney 
disease; CPRD, Clinical Practice Research Datalink; HES, 
Hospital Episode Statistics.
Figure 2 Causal diagram of the association between 
chronic kidney disease and dementia. BMI, body mass index; 
CAD, coronary artery disease; CKD, chronic kidney disease; 
COPD, chronic obstructive pulmonary disease; HF, heart 
failure; RA, rheumatoid arthritis; SES, socioeconomic status; 
SMI, severe mental illness; TIA, transient ischaemic attack.
diagnosis codes (Read codes) suggesting unspecified 
dementia in the current datasets. We focused on the inci-
dence of new (ie, first- ever) diagnoses of dementia in the 
CPRD, and therefore excluded people with any diagnosis 
code of dementia recorded prior to the cohort entry in 
the CKD and matched comparison cohorts.
Covariates
In addition to the matched factors (ie, age, sex, general 
practice and calendar time), we considered ethnicity, SES, 
smoking status, body mass index (BMI) and comorbidities 
including asthma, chronic obstructive pulmonary disease 
(COPD), severe mental illness, depression, epilepsy, 
coronary artery disease, peripheral arterial disease, heart 
failure, stroke and transient ischaemic attack, arterial 
fibrillation, diabetes mellitus, hypertension, rheumatoid 
arthritis, hypothyroidism, osteoporosis and cancer. We 
categorised ethnicity into white, South Asian, black and 
others/mixed based on a previously established algorithm 
using the CPRD and the HES,17 and grouped people 
with missing ethnicity information (neither in the CPRD 
nor the HES) into the white group, based on previous 
studies.26 Individual SES data were categorised into quin-
tiles (Q) from least deprived (Q1) to most deprived (Q5). 
For a small number of patients with missing information 
on individual- level SES, their SES status was replaced with 
the SES status of their general practice (based on their 
postcode). Smoking status was classified as never, current 
and ex- smoker, using the data recorded closest to the 
cohort entry. Each comorbidity was defined as present if 
a relevant diagnosis Read code was recorded at least once 
between the CPRD registration and the cohort entry. 
In addition, prescription records were used to identify 
patients with hypertension and diabetes mellitus.
Statistical analysis to compare matched patients with and 
without CKD
We first showed the baseline characteristics of patients in 
the CKD and matched comparison cohorts, with χ2 tests 
for comparison. We found that the data did not fulfil the 
proportional assumptions for Cox modelling, and there-
fore used unconditional Poisson regression models with 
interactions with a follow- up time to calculate stratum- 
specific rate ratios (RR) for incident dementia diagnosis 
in the first 6 months of follow- up and thereafter (ie, >6 
months after the cohort entry).
Using prior knowledge, a causal diagram containing 
variables that were deemed to be associated with both CKD 
and dementia was created to aid the selection of poten-
tial confounders among the aforementioned covariates 
(figure 2). Demographic factors (age, sex, ethnicity and 
SES), diagnostic factors (general practice and calendar 
time), cardiovascular risk factors (diabetes mellitus, 
smoking and BMI)27 and comorbidities including severe 
mental illness and depression,28 rheumatoid arthritis,29 30 
COPD31 and hypothyroidism32 33 were all considered to 
be associated with both CKD and dementia. We consid-
ered hypertension and cardiovascular diseases (coronary 
artery disease, peripheral arterial disease, heart failure, 
stroke and transient ischaemic attack) to be potentially 
both mediators and confounders between CKD and 
dementia, and therefore decided to show the results of 
models with adjustments for these variables as a sensitivity 
analysis.
Moving on from this conceptual framework, we fitted 
a sequence of models as follows: model 1 was minimally 
adjusted for matched factors (age, sex, general practice 
and calendar time); model 2 was also adjusted for SES, 
ethnicity and shared cardiovascular risk factors (smoking 
status, BMI and diabetes mellitus) as a complete case anal-
ysis; model 3 was additionally adjusted for comorbidities 
considered to be potential confounders (severe mental 
illness, rheumatoid arthritis, COPD, hypothyroidism 
and depression) and model 4 (regarded as a sensitivity 
A
U
TH
O
R 
PR
O
O
F
4 Hiramatsu R, et al. BMJ Open 2020;0:e033811. doi:10.1136/bmjopen-2019-033811
Open access 
analysis) was additionally adjusted for hypertension and 
cardiovascular diseases.
To assess the influence of the competing risk of all- 
cause mortality (ie, if patients with CKD died earlier, they 
may be less likely to be diagnosed with dementia than 
patients without CKD), we also estimated stratum- specific 
RRs for death in the first 6 months of a follow- up and 
thereafter separately, adjusting for the same covariates as 
the Poisson regression analyses for dementia diagnosis. 
We did not conduct a competing risk analysis, because 
our aim here was to describe the incidence of dementia 
and mortality over time in these patients as aetiological 
research, rather than prognostic research that aims to 
predict the probability of dementia in patients with and 
without CKD.34
Statistical analysis to compare patients with different stages 
of CKD in the CKD cohort
To investigate whether there is a graded association 
between the severity of CKD and incident diagnosis of 
dementia in the CKD cohort, the kidney function of 
patients on the day of cohort entry was classified into 
three categories; eGFR 45–60 mL/min/1.73 m2 (namely, 
CKD stage 3a); eGFR 30–44 mL/min/1.73 m2 (namely, 
CKD stage 3b) and eGFR <30 mL/min/1.73 m2 (namely, 
CKD stage 4 or 5).21 35 Similar to the main analysis, the 
aforementioned models (models 1–4) were fitted in the 
first 6 months of follow- ups and thereafter separately, 
regarding CKD stage as exposure and dementia and all- 
cause mortality as separate outcomes.
All statistical analyses were performed in STATA V.14.0.
Patient and public involvement
No patients were involved in the current study.
reSultS
Among the 4 070 806 adults without renal replacement 
therapy registered in the HES- linked CPRD between April 
2004 and March 2014, we identified 264 628 patients with 
CKD (stages 3–5) (figure 1). Of these, 242 349 with CKD 
(mean age 75.4±9.7 years, 39.3% male) were individually 
matched to people without known CKD in terms of age, 
sex and general practice on the same calendar date for 
cohort entry. Then, we excluded 7345 (3.0%) and 8954 
(3.7%) patients with previous diagnoses of dementia 
from the CKD and matched comparison cohort, respec-
tively. Compared with patients without known CKD 
(n=233 395), patients with CKD (n=235 004) were more 
likely to be affluent, ex- smokers and obese (table 1). 
Comorbidities except for osteoporosis and epilepsy were 
more commonly diagnosed for patients in the CKD 
cohort than in the matched comparison cohort.
During the follow- up (median 3.0 years), a total of 
20 658 patients were newly diagnosed with dementia, 
including 11 973 (5.1%) in the CKD cohort (n=235 004) 
and 8685 (3.7%) in the matched comparison cohort 
(n=233 395). The crude incidence rate of dementia 
diagnosis was 11.4/1000 and 9.4/1000 person- years in 
matched patients with and without CKD, respectively. 
Table 2 shows the adjusted RR, comparing patients with 
and without CKD for the incidence of dementia diagnosis 
and all- cause mortality. The adjusted RR (95% CI) for the 
incident dementia diagnosis in model 3 was 1.58 (1.44 
to 1.74) within the first 6 months, and 1.12 (1.08 to 1.16) 
from 6 months onwards. The competing risk of death was 
not strongly suggested: the adjusted RR (95% CI) for all- 
cause mortality in model 3 was 1.01 (0.97 to 1.06) and 
1.12 (1.10 to 1.14) in the first 6 months and thereafter, 
respectively. Additional adjustments for hypertension and 
cardiovascular diseases in model 4 (as a sensitivity anal-
ysis) did not substantially change the results.
Within the CKD cohort, the crude incidence rate 
of dementia diagnosis was 10.7, 13.8, and 13.0/1000 
person- years in patients with CKD stages 3a, 3b and 4 or 
5, respectively. Similarly to the main analysis for patients 
with and without CKD (table 2), the RRs (comparing 
CKD stages 3a, 3b and 4/5) for the incident dementia 
diagnosis were generally greater within the first 6 months 
than thereafter (table 3). Compared with patients with 
CKD stage 3a, the adjusted RR (95% CI) for incident 
dementia diagnosis in model 3 was 1.04 (0.91 to 1.18) 
in patients with CKD stage 3b and 0.94 (0.74 to 1.20) 
in patients with CKD stage 4/5 within the first 6 months 
of follow- ups, while it was 0.97 (0.92 to 1.01) in patients 
with CKD stage 3b and 0.89 (0.80 to 0.98) in patients with 
CKD stages 4/5, from 6 months onwards. Competing risk 
of death (against the incidence of dementia diagnosis) 
was strongly suggested: compared with patients with 
CKD stage 3a, the adjusted RR (95% CI) for all- cause 
mortality in model 3 was 1.85 (1.74 to 1.95) and 4.33 
(4.06 to 4.61) in patients with CKD stages 3b and 4/5 
in the first 6 months, and 1.51 (1.48 to 1.54) and 2.56 
(2.47 to 2.63) after 6 months of follow- ups, respectively. 
Additional adjustments for hypertension and cardiovas-
cular diseases in model 4 (as a sensitivity analysis) did not 
substantially change the results.
DISCuSSIOn
Summary of findings
In this study based on a large English population- based 
primary care cohort, CKD (stages 3–5) was associated 
with incident diagnoses of dementia, after adjusting for 
a wide range of comorbidities. The association was not 
constant over time; dementia was diagnosed at a higher 
rate among patients with CKD soon after they were iden-
tified as having CKD, and the association was weaker after 
6 months. However, there was still a statistically signifi-
cant association between CKD status and dementia (the 
adjusted RR 1.12 (95% CI 1.08 to 1.16) from 6 months 
onwards). There was no graded association between CKD 
stage and the incidence of dementia diagnosis, while 
there was a strong association between CKD stage and 
mortality.
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Table 1 Baseline characteristics of matched patients with and without CKD (stages 3–5) by CKD status and stage
Variables
By CKD status (n=468 399) By CKD stage (n=235 004)
Matched 
patients 
without known 
CKD
(n=233 395)
Matched 
patients with 
CKD
(n=235 004) P value
CKD stage 3a
(n=168 154)
CKD stage 3b
(n=53 285)
CKD stage 4/5
(n=13 565)
N (%) N (%) N (%) N (%) N (%)
Age (mean±SD) 75.0±9.6 75.1±9.7 <0.001 74.1±9.3 77.8±9.6 76.9±12.4
Sex (male) 93 050 (39.9) 93 233 (39.7) 0.173 67 470 (40.1) 19 915 (37.4) 5848 (43.1)
Ethnicity     <0.001       
  White/Non- recorded 229 666 (98.4) 230 906 (98.3) 165 254 (98.3) 52 439 (98.4) 13 213 (97.4)
  South Asian 1772 (0.8) 2260 (1.0) 1625 (1.0) 464 (0.9) 171 (1.3)
  Black 1119 (0.5) 1031 (0.4) 710 (0.4) 200 (0.4) 121 (0.9)
  Others/Mixed 838 (0.4) 807 (0.3) 565 (0.3) 182 (0.3) 60 (0.4)
Socioeconomic status     <0.001       
  Q1 (least deprived) 54 606 (23.4) 51 402 (21.9) 37 868 (22.5) 10 949 (20.6) 2585 (19.1)
  Q2 59 494 (25.5) 58 693 (25.0) 42 482 (25.3) 13 081 (24.6) 3130 (23.1)
  Q3 48 486 (20.8) 49 038 (20.9) 34 908 (20.8) 11 202 (21.0) 2928 (21.6)
  Q4 40 785 (17.5) 43 396 (18.5) 30 561 (18.2) 10 104 (19.0) 2731 (20.1)
  Q5 (most deprived) 30 024 (12.9) 32 475 (13.8) 22 335 (13.3) 7949 (14.9) 2191 (16.2)
Smoking status     <0.001       
  Non- smoker 87 595 (37.5) 77 333 (32.9) 54 547 (32.4) 18 137 (34.0) 4649 (34.3)
  Current smoker 35 633 (15.3) 28 623 (12.2) 20 212 (12.0) 6609 (12.4) 1802 (13.3)
  Ex- smoker 104 637 (44.8) 128 310 (54.6) 93 074 (55.4) 28 283 (53.1) 6953 (51.3)
  Missing 5530 (2.4) 738 (0.3) 321 (0.2) 256 (0.5) 161 (1.2)
Body mass index     <0.001       
  <18.5 6012 (2.6) 4189 (1.8) 2653 (1.6) 1194 (2.2) 342 (2.5)
  18.5–25 82 612 (35.4) 67 768 (28.8) 47 868 (28.5) 15 846 (29.7) 4054 (29.9)
  25–30 78 723 (33.7) 86 089 (36.6) 63 606 (37.8) 18 297 (34.3) 4186 (30.9)
  >30 39 753 (17.0) 62 361 (26.5) 45 974 (27.3) 13 198 (24.8) 3189 (23.5)
  Missing 26 295 (11.3) 14 597 (6.2) 8053 (4.8) 4750 (8.9) 1794 (13.2)
Comorbidities           
  Asthma 27 295 (11.7) 30 586 (13.0) <0.001 22 204 (13.2) 6705 (12.6) 1677 (12.4)
  COPD 14 520 (6.2) 17 740 (7.6) <0.001 12 019 (7.2) 4554 (8.6) 1167 (8.6)
  Diabetes mellitus 23 494 (10.1) 51 442 (21.9) <0.001 35 699 (21.2) 12 145 (22.8) 3598 (26.5)
  Severe mental illness 2808 (1.2) 4281 (1.8) <0.001 3070 (1.8) 950 (1.8) 261 (1.9)
  Epilepsy 3596 (1.5) 3459 (1.5) 0.053 2456 (1.5) 787 (1.5) 216 (1.6)
  Depression 36 309 (15.6) 44 243 (18.8) <0.001 32 224 (19.2) 9718 (18.2) 2301 (17.0)
  Coronary artery disease 26 875 (11.5) 52 603 (22.4) <0.001 35 485 (21.1) 13 471 (25.3) 3647 (26.9)
  Heart failure 7151 (3.1) 22 976 (9.8) <0.001 12 167 (7.2) 7887 (14.8) 2922 (21.5)
  Peripheral arterial 
disease
7236 (3.1) 14 440 (6.1) <0.001 8950 (5.3) 4191 (7.9) 1299 (9.6)
  Stroke or TIA 11 017 (4.7) 18 665 (7.9) <0.001 12 075 (7.2) 5095 (9.6) 1495 (11.0)
  Atrial fibrillation 14 556 (6.2) 28 345 (12.1) <0.001 18 411 (11.0) 7908 (14.8) 2026 (14.9)
  Hypertension 123 843 (53.1) 198 199 (84.3) <0.001 137 848 (82.0) 47 839 (89.8) 12 512 (92.2)
  Rheumatoid arthritis 4129 (1.8) 5874 (2.5) <0.001 4139 (2.5) 1386 (2.6) 349 (2.6)
  Osteoporosis 15 551 (6.7) 15 873 (6.8) 0.211 11 169 (6.6) 3817 (7.2) 887 (6.5)
Continued
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Variables
By CKD status (n=468 399) By CKD stage (n=235 004)
Matched 
patients 
without known 
CKD
(n=233 395)
Matched 
patients with 
CKD
(n=235 004) P value
CKD stage 3a
(n=168 154)
CKD stage 3b
(n=53 285)
CKD stage 4/5
(n=13 565)
N (%) N (%) N (%) N (%) N (%)
  Hypothyroidism 16 608 (7.1) 28 224 (12.0) <0.001 19 859 (11.8) 6709 (12.6) 1656 (12.2)
  Cancer 45 567 (19.5) 52 774 (22.5) <0.001 36 339 (21.6) 12 939 (24.3) 3496 (25.8)
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack.
Table 1 Continued
Table 2 Incident rate ratio for dementia diagnosis and all- cause mortality comparing patients with and without CKD (stages 
3–5) in the first 6 months of follow- up and thereafter
First 6 months of follow- up since the 
cohort entry*
After 6 months of follow- up since the 
cohort entry*
Incidence rate 
ratio (95% CI) 
for diagnosis of 
dementia
Incidence rate ratio 
(95% CI) for all- 
cause mortality
Incidence rate 
ratio (95% CI) 
for diagnosis of 
dementia
Incidence rate 
ratio (95% CI) for 
all- cause mortality
Model 1 No- known CKD 1 1 1 1
  CKD (stages 3–5) 1.52 (1.40 to 1.65) 1.05 (1.01 to 1.10) 1.10 (1.07 to 1.14) 1.14 (1.12 to 1.16)
Model 2 No- known CKD 1 1 1 1
  CKD (stages 3–5) 1.59 (1.44 to 1.75) 1.02 (0.98 to 1.07) 1.12 (1.09 to 1.16) 1.14 (1.12 to 1.16)
Model 3 No- known CKD 1 1 1 1
  CKD (stages 3–5) 1.58 (1.44 to 1.74) 1.01 (0.97 to 1.06) 1.12 (1.08 to 1.16) 1.12 (1.10 to 1.14)
Model 4 No- known CKD 1 1 1 1
  CKD (stages 3–5) 1.60 (1.46 to 1.77) 0.90 (0.86 to 0.93) 1.14 (1.10 to 1.18) 0.97 (0.96 to 0.99)
Model 1: adjusted for age, sex, general practice and calendar time.
Model 2: model 1+adjusted for ethnicity, socioeconomic status, smoking, body mass index and diabetes mellitus.
Model 3: model 2+adjusted for rheumatoid arthritis, chronic obstructive pulmonary disease, hypothyroidism, severe mental disease and 
depression.
Model 4: model 3+adjusted for hypertension and cardiovascular diseases (coronary artery disease, peripheral arterial disease, heart failure 
and stroke or transient ischaemic attack).
*Date when patients satisfied the CKD definition (ie, second estimated glomerular filtration rate <60 mL/min/1.73 m2) and the same date for 
matched patients without known CKD.
CKD, chronic kidney disease.
Comparison with previous studies
Previous cohort studies reported that CKD may be inde-
pendently associated with higher incident dementia 
or cognitive dysfunction.14 36–38 According to a recent 
meta- analysis evaluating population- based prospective 
studies,15 there is a marginally significant association 
between decreased kidney function (eGFR <60 mL/
min/1.73 m2) and incidence of cognitive impairment or 
dementia, at a relative risk of 1.28 (95% CI 0.99 to 1.65). 
This estimate overlapped with our estimate (fully adjusted 
RR of 1.12, 95% 1.08 to 1.16) of the association between 
CKD and dementia diagnosis after 6 months of cohort 
entry. Although there are some differences (eg, identifi-
cation of dementia) between prospective cohort studies 
included in the meta- analysis and our study, based on 
routinely collected primary care data, a long- term weak 
association between CKD status and incident dementia 
appears to be present.
Possible explanations of findings
Dementia and CKD have shared risk factors; in partic-
ular, cardiovascular risk factors (such as smoking, obesity 
and diabetes mellitus) have been mainly considered to 
be a pathophysiological explanation affecting the kidneys 
and brain.6–10 Non- traditional CKD- specific risk factors 
including anaemia, electrolyte disorders (eg, hypona-
traemia), poor nutrition and chronic inflammation (eg, 
oxidative stress and elevated inflammatory cytokines) are 
also considered to play a role in the brain- kidney rela-
tionship.6 7 In our study, there was a greater prevalence 
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Table 3 Incident rate ratio for dementia diagnosis and all- cause mortality comparing patients with different stage of CKD 
(stages 3–5) in the first 6 months of follow- up and thereafter
First 6 months of follow- up since the cohort 
entry*
After 6 months of follow- up since the 
cohort entry*
Incidence rate 
ratio (95% CI) 
for diagnosis of 
dementia
Incidence rate ratio 
(95% CI) for all- cause 
mortality
Incidence rate 
ratio (95% CI) 
for diagnosis of 
dementia
Incidence rate 
ratio (95% CI) for 
all- cause mortality
Model 1 CKD stage 3a 1 1 1 1
  CKD stage 3b 1.04 (0.92 to 1.17) 1.86 (1.78 to 1.95) 0.90 (0.82 to 0.99) 1.53 (1.50 to 1.56)
  CKD stage 4/5 1.07 (0.87 to 1.30) 4.39 (4.15 to 4.65) 0.96 (0.91 to 1.00) 2.61 (2.54 to 2.70)
Model 2 CKD stage 3a 1 1 1 1
  CKD stage 3b 1.04 (0.91 to 1.18) 1.85 (1.75 to 1.97) 0.97 (0.92 to 1.01) 1.51 (1.48 to 1.55)
  CKD stage 4/5 0.94 (0.74 to 1.20) 4.36 (4.09 to 4.64) 0.89 (0.80 to 0.98) 2.57 (2.49 to 2.65)
Model 3 CKD stage 3a 1 1 1 1
  CKD stage 3b 1.04 (0.91 to 1.18) 1.85 (1.74 to 1.95) 0.97 (0.92 to 1.01) 1.51 (1.48 to 1.54)
  CKD stage 4/5 0.94 (0.74 to 1.20) 4.33 (4.06 to 4.61) 0.89 (0.80 to 0.98) 2.56 (2.47 to 2.63)
Model 4 CKD stage 3a 1 1 1 1
  CKD stage 3b 1.05 (0.92 to 1.20) 1.78 (1.68 to 1.89) 0.97 (0.93 to 1.03) 1.47 (1.44 to 1.50)
  CKD stage 4/5 0.85 (0.75 to 1.21) 4.07 (3.82 to 4.33) 0.89 (0.81 to 1.00) 2.41 (2.34 to 2.49)
Model 1: adjusted for age, sex, general practice and calendar time.
Model 2: model 1+adjusted for ethnicity, socioeconomic status, smoking, body mass index and diabetes mellitus.
Model 3: model 2+adjusted for rheumatoid arthritis, chronic obstructive pulmonary disease, hypothyroidism, severe mental disease and 
depression.
Model 4: model 3+adjusted for hypertension and cardiovascular diseases (coronary artery disease, peripheral arterial disease, heart failure 
and stroke or transient ischaemic attack).
*Date when patients satisfied the CKD definition (ie, second estimated glomerular filtration rate <60 mL/min/1.73 m2).
CKD, chronic kidney disease.
of cardiovascular risk factors in the CKD cohort than in 
the matched no- known CKD cohort. However, a statistical 
adjustment for these factors did not fully attenuate the 
association between CKD and dementia diagnosis, even 
in the long- term, suggesting that the non- traditional 
CKD- specific factors (not measured in the current study) 
may be (part of) reasons for the observed CKD- dementia 
association.
The current study highlights a higher relative risk for 
incident diagnosis of dementia among patients with CKD 
in the first 6 months, compared with >6 months since the 
identification of CKD (and the same date for matched 
patients without known CKD). Caution is needed to inter-
pret this result: it is very unlikely that CKD itself, just by 
being detected, causes faster rate of cognitive decline. 
Instead, patients with CKD (based on blood tests) seem 
to get more medical attention (eg, more consultations, 
more tests) compared with patients without CKD, and 
therefore are more likely to be diagnosed with other 
conditions such as dementia. After removing this effect 
in the first 6 months, the remaining weak association 
is probably closer to the true association between CKD 
and dementia. In addition, a greater mortality was seen 
in advanced CKD stages, suggesting that patients with 
advanced CKD are more likely to die before they would be 
diagnosed with dementia (ie, competing mortality risk).
Strengths and weaknesses
The strengths of the current study include its large sample 
size, which allowed us to conduct a statistical adjustment 
for a wide range of comorbidities and subgroup analyses. 
In addition, the CPRD is representative of the general 
English population, and therefore the study result is likely 
to be generalisable to the wider country.16 Furthermore, 
our previous validation study suggested that the CPRD 
captures most people with decreased kidney function 
(eGFR <60 mL/min/1.73 m2), compared with nationally 
representative statistics (Health Survey for England), 
based on blood test results (without using recorded 
diagnosis of CKD).23 In contrast to previous studies that 
have associated single- time point measures of eGFR with 
incident dementia, here, we used the clinical defini-
tion including the chronicity of CKD to investigate the 
association. In the statistical analyses, care was taken to 
investigate the statistical assumptions of the models that 
were fitted, thereby identifying the time dependency of 
dementia diagnosis in routine care.
However, we need to acknowledge several limitations. 
First, the study outcome was defined as dementia diag-
nosis recorded by primary care physicians. According to 
a previous study,24 25 dementia diagnosis in UK primary 
care showed a highly positive predictive value, but its 
sensitivity remains unknown. It is very possible that the 
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sensitivity of dementia diagnosis is low, compared with 
dementia diagnosis based on more objective tools such 
as the Mini Mental State Examination, which would result 
in an underestimation of the association between CKD 
and incident dementia. In addition, we were unable to 
classify the type of dementia (eg, vascular dementia and 
Alzheimer’s disease) accurately in our datasets, although 
the associations between each type of dementia and CKD 
may be different, from the pathophysiological perspec-
tive. Second, although we used the Chronic Kidney 
Disease Epidemiology Collaboration equation to estimate 
people’s eGFR from serum creatinine, this approach 
might have overestimated kidney function in individuals 
who have lower muscle mass, resulting in a misclassifica-
tion of CKD status among frail individuals who are at risk 
of dementia,39 again leading to an underestimation of the 
true association. In addition, we acknowledge that protein-
uria is an important prediction marker for dementia,9 
and proteinuria is also part of (early stage) CKD defini-
tion.21 35 However, we did not define (early stage) CKD 
based on proteinuria, stratify patients by level of protein-
uria or quantify the association between proteinuria and 
incidence of dementia. This was because proteinuria was 
infrequently checked in the CPRD (unless patients had 
diabetes mellitus),40 and it would not be appropriate to 
assume that people who did not undergo urine testing 
did not have proteinuria. For this reason, our CKD cohort 
might have missed some patients with true CKD, while 
the matched comparison cohort (no- known CKD cohort) 
might have included some patients with CKD, possibly 
diluting the observed association between CKD and 
dementia.
Clinical and research implications
As for clinical implications of the current study, co- oc-
currence of CKD and dementia in the primary care 
setting may mean that a subset of people with CKD are 
detected with having dementia, as they struggle coping 
with the multimorbidity that is frequently found in CKD. 
This study and earlier work showing the extent of mild 
cognitive impairment in early CKD41 suggest that the 
current system of a brief primary care appointment may 
not enable patients to manage their health problems due 
to the difficulty recalling complex information, which in 
turn may be an additional factor why people with CKD 
have poor health outcomes. A tailor- made consultation 
for high- risk patients may be needed.
As for research implications, our study highlights that a 
careful approach is needed to investigate a disease- disease 
association in routinely collected data such as the CPRD. 
We suggested that the true association between CKD 
and dementia would be much smaller than the apparent 
association estimated without considering potential 
biases (related to time since diagnosis, confounding and 
competing risk of mortality) inherent in the real- world 
data.
In addition, further research using traditional cohort 
data is needed to independently determine whether 
better management of risk factors present in people with 
CKD may diminish the impacts on cognitive impairment, 
and the observed long- term associations with dementia.
COnCluSIOn
Using English primary care routine data, this study showed 
a co- occurrence of the detection of CKD and dementia 
in real- world clinical practice in the first 6 months after 
CKD detection, while a weak association was suggested in 
the long run. There was no positive association between 
CKD severity and dementia diagnosis, most likely due to 
competing mortality.
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